Takeover bid for Arana
Friday, 27 February, 2009
Arana Therapeutics is in discussions with an unnamed party about a possible takeover bid for the cash-rich company.
Arana, itself the result of a merger between Evogenix and Peptech, has a full and promising pipeline and a very strong cash position of $175 million.
It discontinued its age-related macular degeneration project PMX53 recently, but has strong candidates in inflammatory diseases. Lead candidate ART621, an anti-TNF antibody, is nearing the end of a Phase II trial for psoriasis and is beginning Phase II for rheumatoid arthritis.
The company’s market capitalisation is a very healthy $190 million and its finances strong enough to have carried out a share buy-back.
The company said it would make an announcement on both the bid and the search for a new CEO in due course.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
